Company
NanoValent Pharmaceuticals, Inc. (NanoValent/NVP) is a privately-held company with headquarters in Bozeman (MT) collaborating with Children’s Hospital Los Angeles (CHLA) as well as other US academic partners to develop novel therapeutic options with enhanced target and delivery characteristics. NanoValent possesses a highly experienced core management team with a proven track record of success, supported by a strong clinical and operational support group.
STATUS
NVP has so far developed three HPLN (Hybrid Polymerized Liposomal Nanoparticle) based TNS (Targeted Nanosphere) candidates in oncology: NV101(Doxorubicin-anti-CD99), NV102 (Doxorubicin-anti-CD19) and our lead NV103(Irinotecan-anti-CD99).
NV103 is now approaching IND status and being validated in CD99 expressing tumors such as Glioblastoma, Pancreatic, Ovarian and Ewing Sarcoma. Other validating programs with NV101 (in Ewing Sarcoma and CD99 expressing tumors) and NV102 in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are also scheduled.
In addition NVP has developed a modified HPLN structure specifically designed for optimising nucleic acid based therapy delivery. Also, with Boston University, NV201, a fibrin targeted, PSM (Polymerized Shell Microbubble) ultrasound activated microsphere (TMS) shows early promise in diagnosing and treating surgical adhesions.
Overall, our technology promises to enables significant enhancement of the performance of therapeutic agents. For example, NV102 increases tumor-killing efficacy 10-12 fold in vitro, compared to untargeted HPLN loaded with Doxorubicin and almost 40 fold versus conventional Doxorubicin. With NV101 the enhancement seen was even greater, 40 fold versus commercially available Doxo-liposomes and 80 fold versus Doxorubicin. However having seen even greater and broader power and control in NV103 versus already approved benchmark products, we decided to make this our leading candidate. Once we achieve clinical validation in NV103 we believe NanoValent will rapidly progress as a company able to apply our IP to various other challenges, both in adult oncology and beyond.